factors that increase pancreatitis risk with glp 1 initiation Frontiers Risk of all–cause death and

The research from the FDA Adverse Event Reporting System revealed elevated reporting odds ratios for alopecia with semaglutide (2.46) and tirzepatide (1.73), though notably not with older GLP-1 medications like liraglutide or dulaglutide

there are millions of hair follicles on the face

The payoff is worth it for some people

That means that the average woman in this age range is right on the dividing line between overweight and obese. Given an average height of 54, this average woman should weigh 146-1/2 lbs to achieve a BMI of 25, implying a weight loss of ~30 lbs, or ~17% of her beginning weight.) Fact #2: Only about a third of women are still on their GLP-1 RA drug after 1 year

Risk: Higher cagrilintide dose will likely increase GI side effects and discontinuation rates